Physician profile
Mercedes Bello
NPI 1598069700
$13,630.28
in general payments reported to CMS, 2019-2025
26 companies · $3,049 in 2025
The $3,049 reported for 2025 was more than what 88% of Sleep Medicine (Pediatrics) providers received nationally (typical 2025 total: $235).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,252 · 2020: $543 · 2021: $1,163 · 2022: $2,775 · 2023: $3,187 · 2024: $1,661 · 2025: $3,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,897.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,037.79 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Supernus Pharmaceuticals, INC. | $2,523.58 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $1,306.43 | 2021-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $1,194.05 | 2020-2025 | |
| Neurelis, INC. | $765.10 | 2021-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $693.63 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $682.20 | 2021-2023 | Jornay Pm |
| Eisai INC. | $521.11 | 2019-2022 | |
| Tris Pharma INC | $347.50 | 2019-2025 | Dyanavel Xr |
| Greenwich Biosciences, INC. | $323.48 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $182.46 | 2023 | Aptiom |
| Sk Life Science, INC. | $175.02 | 2022-2023 | |
| Livanova USA, INC. | $148.10 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | Ultomiris |
| Immedica Pharma US, INC. | $104.68 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $100.14 | 2019-2021 | |
| Harmony Biosciences LLC | $73.42 | 2025 | |
| Aquestive Therapeutics, INC. | $66.97 | 2019-2022 | |
| Aucta Pharmaceuticals, INC. | $54.57 | 2025 | Motpoly Xr |
| Aprecia Pharmaceuticals, LLC | $45.16 | 2023 | Spritam |
| Mallinckrodt Enterprises LLC | $39.40 | 2019 | |
| Resmed Corp | $38.08 | 2022 | |
| Azurity Pharmaceuticals, INC. | $27.63 | 2025 | Zonisade |
| Biocodex, INC. | $21.75 | 2023 | Diacomit |
| Shire North American Group INC | $17.92 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mercedes Bello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.